(FDA) approved TCRT-ESO-A2 new drug clinical trial application (IND), the new drug can enter clinical trials. Basics of drugs licensed for clinical trials in the United States: 1, Drug Name: TCRT-ESO-A2
Ganley Pharmaceuticals has submitted an application for a U.S. clinical trial of NASH's new drug ASC42
Time of Update: 2021-03-02
Pharmaceutical Co., Ltd. today announced that it has submitted a clinical trial application (IND) for the non-alcoholic fatty hepatitis (NASH) candidate drug ASC42 to the FDA.
A major pharmaceutical province intends to issue guidance
Time of Update: 2021-03-02
the quality and safety of drugs in the logistics sector, the Shanghai Municipal Drug Administration issued a notice on the "Shanghai Drug Modern Logistics Guidance (Draft for Comments)" for public consultation. The Opinions
Stone Pharmaceutical Group's application for the listing of anticancer drugs is to be included in the priority review
Time of Update: 2021-03-02
lipid body is the self-developed mitoxyquinone lipid system agent, is a 2.2 class of improved new drugs, stone pharmaceutical group has full intellectual property rights. In 2017, the FDA granted the drug orphan status for the treatment of external T
The release of an important national notice will affect all arms companies
Time of Update: 2021-03-02
procurement agency as soon as possible to organize the province's bid hanging network enterprises as required to submit "pharmaceutical enterprise prices and marketing behavior credit commitment", to improve service awareness, online and offline parallel
China National Pharmaceutical Group submitted an application for the listing of the new crown vaccine
Time of Update: 2021-03-01
, deputy general manager of China National Pharmaceutical Group Co., Ltd., said China National Pharmaceutical Group has submitted a new crown vaccine listing application to the State Drug Administration.
Britain has agreed to buy Sbach Therapeutics from Roche Pharmaceuticals
Time of Update: 2021-03-01
China's medicine authority said its investigation also identified several innovative non-gene therapy products being developed that could be viable alternatives to Roche and Sbach treatments, ensuring patients had sufficient options in the future and unconditionally approved the move.
Junshi Bio cooperates with Lilly Pharmaceuticals to develop preventive and therapeutic antibody therapies
Time of Update: 2021-03-01
May 4, Regency Bio and Lilly Pharmaceuticals announced that they had reached an agreement to jointly develop potential preventive and therapeutic antibody therapies for new coronary pneumonia caused by the new SARS-CoV-2 coronavirus.
Water circulation is important and complex in photodynoploy
Time of Update: 2021-03-01
the water cycle in the fluctuation of light under the important regulatory role, but between different species, water cycle protection strategies also exist diversity and complexity. The five findings were published in international journals such as Environmental and Experimental Botany, Plant Science, and Bioeneerology.
Another multinational pharmaceutical executive is leaving! BMS has a wave of departures after the acquisition of the new base?
Time of Update: 2021-03-01
of a company's executives often leads to a series of knock-on effects that change the company's organizational structure, business plan, and even overall style. Of course, BMS's personnel changes this year are mainly aimed at matching the new company after
To support the development of pharmaceutical services, three jobs will be done
Time of Update: 2021-03-01
to the representative's proposal to implement compensation for pharmaceutical services and strengthen the construction of a team of pharmacists to promote rational drug use. On the introduction of standardized pharmaceutical service standards
Bayer hired Marian de Barker of Johnson and Johnson to lead the pharmaceutical business
Time of Update: 2021-03-01
DeBaker recently served as Vice President of Operations and Divestitures at Johnson and Johnson Pharmaceuticals, responsible for leading Bayer's global external pharmaceutical growth strategy and activities in all key areas of pharmaceutical innovation and alliance management.
The new gene of low oxygen adaptation has important potential functions in solid tumors
Time of Update: 2021-02-28
Reporter November 3 from the Kunming Institute of Zoology was informed that the institute's researchers have recently revealed in the development of low oxygen adaptation and non-small cell lung cancer, an amplified protein important
China Resources Shuanghe acquired Xiangzhong Pharmaceuticals to take an 80% share of the region
Time of Update: 2021-02-28
June 4, China Resources Shuanghe announced that it will use its own funds to acquire a 40% stake in China Resources Shuanghe Limin Pharmaceuticals (Jinan) Co., Ltd. for 847.66 million yuan.
Keystone Pharmaceuticals filed an Ivosidenib application
Time of Update: 2021-02-28
therapy, about 35% to 40% of young patients can achieve complete remission, but only about 10% of elderly patients can achieve more than 3 years of survival. Most AML patients eventually develop drug resistance or recurrence into R/R AML, follow-up
"With gold" sales lost the four basic skills necessary for pharmaceutical people!
Time of Update: 2021-02-28
ability of substitutes, supplier bargaining power, buyer's bargaining power and other five forces; 03, fast and effective dissemination of brand “ Passing "word to the left side, to the right side
The decline in research and development power of pharmaceutical giants has slowed the growth rate of the number of research and development enterprises
Time of Update: 2021-02-28
In 2018, when Big Mac mergers and acquisitions activity declined, followed by a decline in the number of products under development, only six of top25 pharmaceutical companies are studying an unprecedented increase in the number of drugs.
In the first half of the year, the fund's top 30 stocks were 90% heavy-stock pharmaceutical stocks
Time of Update: 2021-02-28
States" market, for the public fund to contribute a lot of income. The performance of the two fund managers was eye-catching in the first half of this year, the market as a whole fell, with only leisure services, pharmaceuticals
Kangmei took another county distribution of a number of pharmaceutical companies to buy sanjia hospital
Time of Update: 2021-02-28
experts think that the hospital's public welfare or not and the ownership of the hospital has no absolute relationship. , for example, many social hospitals in the UK are public good, but the government can still fund them. On the other way
